Cargando…

Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA

BACKGROUND: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) show certain overlaps: A subset of patients with PsA can develop axial involvement (axial PsA, axPsA), while a subset of patients with axSpA presents with psoriasis (axSpA+pso). Treatment strategy for axPsA is mostly based on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Regierer, Anne Constanze, Weiß, Anja, Proft, Fabian, Baraliakos, Xenofon, Behrens, Frank, Poddubnyy, Denis, Schett, Georg, Lorenz, Hanns-Martin, Worsch, Matthias, Strangfeld, Anja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Psoriatic Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008170/ https://www.ncbi.nlm.nih.gov/pubmed/36898762 http://dx.doi.org/10.1136/rmdopen-2022-002837

Ejemplares similares

Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort
por: Reich, Andreas, et al.
Publicado: (2023)

High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex
por: Albrecht, Katinka, et al.
Publicado: (2023)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2021)

Treat-to-target in PsA: methods and necessity
por: Dures, Emma, et al.
Publicado: (2020)

Same, same or different? Commonalities and differences between spondyloarthritis and its subsets of axial and peripheral spondyloarthritis with psoriatic arthritis and its diverse phenotypes
por: Proft, Fabian, et al.
Publicado: (2023)

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021)

Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
por: Richette, Pascal, et al.
Publicado: (2023)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
por: McInnes, Iain B, et al.
Publicado: (2021)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
por: Mease, Philip J, et al.
Publicado: (2018)

Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce
por: De Marco, Gabriele, et al.
Publicado: (2023)

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022)

Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study
por: Proft, Fabian, et al.
Publicado: (2022)

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
por: Lindström, Ulf, et al.
Publicado: (2021)

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
por: Coates, Laura C, et al.
Publicado: (2023)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: a randomised controlled trial
por: Thomsen, Ruth Stoklund, et al.
Publicado: (2018)

Axial psoratic arthritis: are you a lumper or a splitter?
por: Coates, Laura C, et al.
Publicado: (2023)

Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities
por: Koehm, Michaela, et al.
Publicado: (2023)

Tolerability of low to moderate biomechanical stress during leisure sport activity in patients with psoriasis and psoriatic arthritis
por: Fagni, Filippo, et al.
Publicado: (2023)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
por: Braun, Juergen, et al.
Publicado: (2023)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
por: Coates, Laura C, et al.
Publicado: (2022)

Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
por: Souto-Carneiro, Margarida, et al.
Publicado: (2020)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
por: Pournara, Effie, et al.
Publicado: (2021)

Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy
por: Robinson, Philip C., et al.
Publicado: (2019)

Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (Be-)GIANT multicentre cohorts
por: de Hooge, Manouk, et al.
Publicado: (2023)

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
por: Gladman, Dafna D, et al.
Publicado: (2018)

Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease
por: Mellor, Liliana F, et al.
Publicado: (2022)

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
por: Nash, Peter, et al.
Publicado: (2018)

Non-radiographic versus radiographic axSpA: what’s in a name?
por: Michelena, Xabier, et al.
Publicado: (2020)

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
por: Kristensen, Lars Erik, et al.
Publicado: (2022)

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2022)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
por: Mease, Philip J, et al.
Publicado: (2020)

Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression
por: Stal, Rosalinde, et al.
Publicado: (2020)

How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management
por: Fatica, Mauro, et al.
Publicado: (2022)

Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti–tumor necrosis factor therapies
por: Saad, Amr A, et al.
Publicado: (2010)

Investigation of association of the IL12B and IL23R genes with psoriatic arthritis
por: Filer, Charlotte, et al.
Publicado: (2008)

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study
por: Gladman, D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7ob2edk181ii3msr3s624vgdcd